Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Astrazeneca (AZNCF) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Astrazeneca (AZNCF) over the last 16 years, with Q4 2025 value amounting to $3.1 billion.

  • Astrazeneca's Cost of Revenue rose 1442.2% to $3.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $10.6 billion, marking a year-over-year increase of 417.36%. This contributed to the annual value of $10.6 billion for FY2025, which is 417.36% up from last year.
  • According to the latest figures from Q4 2025, Astrazeneca's Cost of Revenue is $3.1 billion, which was up 1442.2% from $2.8 billion recorded in Q3 2025.
  • Over the past 5 years, Astrazeneca's Cost of Revenue peaked at $4.6 billion during Q4 2021, and registered a low of $1.9 billion during Q1 2021.
  • Over the past 5 years, Astrazeneca's median Cost of Revenue value was $2.6 billion (recorded in 2024), while the average stood at $2.7 billion.
  • As far as peak fluctuations go, Astrazeneca's Cost of Revenue skyrocketed by 29538.08% in 2021, and later tumbled by 4574.2% in 2023.
  • Astrazeneca's Cost of Revenue (Quarter) stood at $4.6 billion in 2021, then crashed by 37.3% to $2.9 billion in 2022, then decreased by 20.41% to $2.3 billion in 2023, then grew by 18.07% to $2.7 billion in 2024, then grew by 14.42% to $3.1 billion in 2025.
  • Its Cost of Revenue stands at $3.1 billion for Q4 2025, versus $2.8 billion for Q3 2025 and $2.5 billion for Q2 2025.